Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA-based therapeutics and vaccines can be delivered via the below-mentioned approaches.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

MAY 15, 2023

The sBLA is based on results from the phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept. 1,2 Vabysmo’s safety profile was consistent with previous trials.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

APRIL 12, 2023

The abstracts showcase the strength and breadth of Roche’s Ophthalmology portfolio, including post-hoc data from phase III Vabysmo® (faricimab) studies that support its benefit in drying retinal fluid in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Antibody 40

Antibody In-Vitro Development Trials 40